Loading clinical trials...
Loading clinical trials...
A Phase 1b Dose-escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX2853 in Subjects With Advanced Malignancies
Conditions
Interventions
PLX2853
Locations
5
United States
Honor Health
Scottsdale, Arizona, United States
Sylvester Comprehensive Cancer Center / University of Miami Miller School of Medicine
Miami, Florida, United States
Columbia University Medical Center
New York, New York, United States
South Texas Accelerated Research Therapeutics (START)
San Antonio, Texas, United States
Virginia Cancer Specialists
Fairfax, Virginia, United States
Start Date
September 12, 2017
Primary Completion Date
June 7, 2021
Completion Date
June 7, 2021
Last Updated
July 25, 2022
NCT07177937
NCT06043817
NCT05671510
NCT06257264
NCT06646276
NCT07144280
Lead Sponsor
Opna Bio LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions